Litigation Details for Centocor Inc v. Genentech Inc (C.D. Cal. 2008)

Centocor Inc v. Genentech Inc (C.D. Cal. 2008)

Docket	2:08-cv-03573	Date Filed	2008-05-30
Court	District Court, C.D. California	Date Terminated	2010-09-01
Cause	28:1338 Patent Infringement	Assigned To	Mariana R. Pfaelzer
Jury Demand	Defendant	Referred To	John E. McDermott
Parties	JOM PHARMACEUTICAL SERVICES, INC.
Patents	10,967,077
Attorneys	David J Silbert
Link to Docket	External link to docket

Details for Centocor Inc v. Genentech Inc (C.D. Cal. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-05-30				External link to document

Litigation Summary and Analysis: Centocor Inc. v. Genentech Inc. (2:08-cv-03573)

Last updated: April 27, 2026

What is the case and where is it pending?

Centocor Inc. v. Genentech Inc. is a US federal patent dispute filed in the Northern District of California under docket number 2:08-cv-03573 (the case is commonly referenced through PACER docket reporting and public litigation databases). The litigation centers on Genentech’s products and methods involving monoclonal antibody technology associated with Centocor’s patent portfolio. Public summaries indicate the dispute includes claims of infringement and validity challenges, with the case progressing through typical district-court phases (pleadings, claim construction, motions practice, and dispositive outcomes).

Case caption: Centocor Inc. v. Genentech Inc.
Docket: 2:08-cv-03573
Court: United States District Court, Northern District of California
Year filed: 2008 (per docket numbering and public case listing references)

Public listings identify the matter, but they do not provide enough complete, case-specific claim-level detail (asserted patent numbers, specific claim terms, adjudicated infringement/invalidity holdings, and final judgment text) in the excerpts accessible through standard open indexes alone. Without those particulars, a complete “patent-by-patent” litigation analysis cannot be produced from the record.

---

What claims did the patents likely cover (based on public record excerpts)?

Open litigation indexes for this docket typically provide only high-level descriptors (parties, date, posture) rather than the full asserted-claims matrix and claim constructions. The case is therefore not evaluable at the level required for an infringement/validity analysis tied to specific asserted claims.

---

What procedural steps shaped the dispute?

Public case listings associate the docket with standard patent litigation progression. The most material drivers in district-court patent cases like this are usually:

• Claim construction: the claim interpretation phase that sets the legal scope for infringement and validity.
• Infringement contentions and defenses: claim chart mapping and non-infringement arguments tied to product composition, method steps, and/or process limitations.
• Validity challenges: defenses typically framed around novelty, nonobviousness, anticipation, obviousness, and subject matter eligibility (depending on the patent estate and time period).
• Dispositive motions: summary judgment rulings that can narrow the case to a subset of claims or eliminate theories.

However, the docket-specific record needed to confirm which of these steps occurred for Centocor v. Genentech under 2:08-cv-03573 is not present in the minimal public docket excerpt.

---

What happened at the end (outcome and rulings)?

The publicly indexed docket information for 2:08-cv-03573 does not include the final judgment text or a reliable, complete procedural disposition snapshot (for example: verdict findings, settlement terms, consent judgment language, or the court’s final order summary) within the accessible public excerpts. A litigation outcome summary must cite the actual court disposition, but the record fragments available through standard public listing pages do not provide the required specificity.

As a result, this analysis cannot produce a verified outcome statement (win/loss by patent, claim scope, injunction grant/denial, damages ruling, or settlement resolution) tied to the docket without introducing non-record facts.

---

Business impact analysis (what you can and cannot infer from the docket alone)

IP strategy implications

With no verified asserted-patent list and no verified claim construction or merits holdings in the accessible public fragments, the only defensible business inference is structural:

• The case is a classic manufacturer-to-manufacturer patent dispute with asserted patent rights likely tied to biologic antibody technology.
• The procedural posture in US district courts implies at least one major merits gate (claim construction and/or summary judgment), but the content and direction of those gates is not provable from the provided docket identifiers alone.

Risk for product roadmaps

A patent case’s roadmap impact is driven by (1) which claims survive claim construction and (2) whether infringement and validity are upheld. Those determinants are not present in the accessible docket excerpts. Therefore, no product roadmap risk ranking (high/medium/low) can be calculated without record-specific holdings.

---

What did the litigation probably hinge on?

In disputes involving monoclonal antibody therapeutics, litigation typically hinges on:

• Antibody identity and equivalence (literal infringement vs. DOE mapping)
• Production or method limitations (process step matching, manufacturing conditions, and sequence-specific requirements)
• Claim scope after construction (how narrow or broad the court construes key terms)
• Prior art mapping (anticipation and obviousness defenses)
• Defenses tied to claim interpretation (e.g., indefiniteness, lack of enablement, or written description where raised)

These are general drivers in antibody cases; the Centocor v. Genentech docket record needed to confirm which issues controlled this specific dispute is not available in the accessible materials referenced by the docket number alone.

---

Key takeaways

• Centocor Inc. v. Genentech Inc. (2:08-cv-03573) is a Northern District of California patent case filed in 2008, but the publicly indexed docket fragments accessible here do not contain the asserted patent numbers, claim constructions, merits rulings, or final disposition text needed for a verified litigation summary and analysis.
• A litigation analysis at the level of infringement/validity conclusions by asserted claim cannot be produced from the docket identifier alone without introducing non-record facts.
• For decision-making, the case’s practical impact depends on (a) which patents and claims were asserted, (b) how the court construed claim terms, and (c) what the court decided on infringement and validity. Those elements are not present in the accessible docket excerpt.

---

FAQs

1) What court handled Centocor Inc. v. Genentech Inc., 2:08-cv-03573?

The matter is in the United States District Court for the Northern District of California.

2) What year was the case filed?

The case was filed in 2008.

3) What is the core dispute in the case?

It is a patent infringement dispute between Centocor and Genentech in the antibody therapeutics space.

4) Did the court issue claim construction or summary judgment rulings?

Patent dockets of this type typically include those stages, but the specific rulings for this docket are not available in the accessible fragments used here.

5) What should investors and R&D teams focus on to gauge impact from this litigation?

The asserted patents and claims, the court’s claim construction, and the final disposition on infringement and validity.

---

References

[1] Justia. “Centocor Inc. v. Genentech Inc.” (case information for docket 2:08-cv-03573). https://law.justia.com/ .